Scientific reports · 2019
Determination of the pathogenicity of known COL4A5 intronic variants by in vitro splicing assay.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Horinouchi Tomoko, Nozu Kandai, Yamamura Tomohiko, Minamikawa Shogo, Nagano China, Sakakibara Nana, Nakanishi Koichi, Shima Yuko, Morisada Naoya, Ishiko Shinya, Aoto Yuya, Nagase Hiroaki, Takeda Hiroki, Rossanti Rini, Kaito Hiroshi, Matsuo Masafumi, Iijima Kazumoto
Аннотация
X-linked Alport syndrome (XLAS) is a congenital renal disease caused by mutations in COL4A5. In XLAS cases suspected of being caused by aberrant splicing, transcript analysis needs to be conducted to determine splicing patterns and assess the pathogenicity. However, such analysis is not always available. We conducted a functional splicing assay using a hybrid minigene for seven COL4A5 intronic mutations: one was identified by us and six were found in the Human Gene Mutation Database. The minigene assay revealed exon skipping in four variants, exon skipping and a 10-bp insertion in one variant, and no change in one variant, which appeared not to be pathogenic. For one variant, our assay did not work. The results of all three cases for which transcript data were available were consistent with our assay results. Our findings may help to increase the accuracy of genetic test results and clarify the mechanisms causing aberrant splicing.